Outputs (956)

Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity (2009)
Journal Article
Bournazos, S., Hart, S. P., Chamberlain, L. H., Glennie, M. J., & Dransfield, I. (2009). Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity. Journal of Immunology, 182(12), 8026-8036. https://doi.org/10.4049/jimmunol.0900107

Binding of Igs to myeloid cells via FcR is a key event in the control of innate and acquired immunity. FcγRIIa (CD32a) is a receptor for multivalent IgG expressed predominantly by myeloid cells, and its association with microdomains rich in cholester... Read More about Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity.

Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? (2009)
Journal Article
Johnson, M., & Maraveyas, A. (2009). Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. The British Journal of Cancer, 100(12), 1837-1841. https://doi.org/10.1038/sj.bjc.6605091

After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is... Read More about Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins (2009)
Journal Article
Carradice, D., Mekako, A. I., Hatfield, J., & Chetter, I. C. (2009). Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins. British journal of surgery, 96(4), 369-375. https://doi.org/10.1002/bjs.6556

Background: The management of residual varicosities following endovenous laser therapy (EVLT) for varicose veins is contentious. Ambulatory phlebectomy may be performed concomitantly with the initial EVLT, or sequentially as a secondary procedure. Th... Read More about Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins.

Laser venous interventions (2009)
Journal Article
Carradice, D., & Chetter, I. (2009). Laser venous interventions. Vascular Disease Management, 6(2), 41 - 46

Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation (2009)
Journal Article
Barnett, C., Vanicek, N., Polman, R., Hancock, A., Brown, B., Smith, L., & Chetter, I. (2009). Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation. Prosthetics and orthotics international, 33(2), 135-147. https://doi.org/10.1080/03093640902751762

Introduction: Physiotherapists routinely prescribe the use of two different early walking aids (EWAs) to individuals who have recently undergone unilateral transtibial amputation. No research to date has investigated the kinematic gait patterns of tr... Read More about Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation.

Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan (2009)
Journal Article
Faruqi, S., Fathi, H., & Morice, A. H. (2010). Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. International journal of cardiology, 144(3), e43-e45. https://doi.org/10.1016/j.ijcard.2008.12.065

Sitaxentan, a highly-selective endothelin receptor antagonist (ETRA) and bosentan a non-selective ETRA are both approved for the treatment of idiopathic pulmonary arterial hypertension (iPAH). Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor use... Read More about Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J.-M., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study (2009)
Journal Article
Sathyapalan, T., Kilpatrick, E. S., Coady, A. M., & Atkin, S. L. (2009). The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 94(1), 103-108. https://doi.org/10.1210/jc.2008-1750

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular morbidity, whereas statins are proven to reduce cardiovascular mortality and morbidity through lipid-lowering and perhaps through their pleiotropic effects.... Read More about The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine (2008)
Journal Article
Sadofsky, L. R., Campi, B., Trevisani, M., Compton, S. J., & Morice, A. H. (2008). Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Experimental Lung Research, 34(10), 681-693. https://doi.org/10.1080/01902140802339623

American guidelines, unlike European guidelines, support the use of antihistamines as a first line of treatment for some causes of chronic cough. Transient receptor potential vanilloid-1 (TRPV1) is an ion channel activated by the tussive agents capsa... Read More about Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine.